Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -118.82 Million SEK | 1.74% |
| 2022 | -120.04 Million SEK | -61.56% |
| 2021 | -73.2 Million SEK | -100.84% |
| 2020 | -36.96 Million SEK | -52.18% |
| 2019 | -23.03 Million SEK | -12.7% |
| 2018 | -21.26 Million SEK | -67.86% |
| 2017 | -12.67 Million SEK | -45.06% |
| 2016 | -8.73 Million SEK | -38.02% |
| 2015 | -6.32 Million SEK | -29.98% |
| 2014 | -4.86 Million SEK | -9.29% |
| 2013 | -4.45 Million SEK | -26.95% |
| 2012 | -3.5 Million SEK | -76.57% |
| 2011 | -1.98 Million SEK | 10.28% |
| 2010 | -2.21 Million SEK | -52.99% |
| 2009 | -1.44 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -29.28 Million SEK | 31.01% |
| 2024 Q2 | -29.91 Million SEK | -19.09% |
| 2023 Q4 | -28.94 Million SEK | -14.45% |
| 2023 FY | - SEK | 1.74% |
| 2023 Q1 | -26.46 Million SEK | 29.4% |
| 2023 Q2 | -30.02 Million SEK | -13.46% |
| 2023 Q3 | -25.28 Million SEK | 15.78% |
| 2022 Q3 | -24.72 Million SEK | 34.95% |
| 2022 Q4 | -37.48 Million SEK | -51.57% |
| 2022 FY | - SEK | -61.56% |
| 2022 Q2 | -38.01 Million SEK | -109.46% |
| 2022 Q1 | -18.15 Million SEK | 15.79% |
| 2021 Q3 | -16.95 Million SEK | 13.61% |
| 2021 Q1 | -15.08 Million SEK | -24.58% |
| 2021 FY | - SEK | -100.84% |
| 2021 Q2 | -19.62 Million SEK | -30.14% |
| 2021 Q4 | -21.55 Million SEK | -27.1% |
| 2020 Q3 | -8.99 Million SEK | 12.06% |
| 2020 Q1 | -6.25 Million SEK | 2.66% |
| 2020 FY | - SEK | -52.18% |
| 2020 Q4 | -12.1 Million SEK | -34.64% |
| 2020 Q2 | -10.22 Million SEK | -63.42% |
| 2019 Q3 | -5.1 Million SEK | 15.44% |
| 2019 FY | - SEK | -12.7% |
| 2019 Q2 | -6.03 Million SEK | 5.69% |
| 2019 Q1 | -6.39 Million SEK | 21.86% |
| 2019 Q4 | -6.42 Million SEK | -25.97% |
| 2018 Q4 | -8.18 Million SEK | -120.43% |
| 2018 FY | - SEK | -67.86% |
| 2018 Q2 | -5.38 Million SEK | -35.2% |
| 2018 Q1 | -3.98 Million SEK | -11.36% |
| 2018 Q3 | -3.71 Million SEK | 30.96% |
| 2017 FY | - SEK | -45.06% |
| 2017 Q4 | -3.57 Million SEK | -51.12% |
| 2017 Q3 | -2.36 Million SEK | 16.81% |
| 2017 Q2 | -2.84 Million SEK | 26.76% |
| 2017 Q1 | -3.88 Million SEK | -14.11% |
| 2016 Q4 | -3.4 Million SEK | -89.74% |
| 2016 FY | - SEK | -38.02% |
| 2016 Q3 | -1.79 Million SEK | 3.34% |
| 2016 Q2 | -1.85 Million SEK | -10.23% |
| 2016 Q1 | -1.68 Million SEK | 0.17% |
| 2015 Q3 | -1.55 Million SEK | 12.75% |
| 2015 Q4 | -1.68 Million SEK | -8.37% |
| 2015 Q1 | -1.3 Million SEK | 17.73% |
| 2015 FY | - SEK | -29.98% |
| 2015 Q2 | -1.78 Million SEK | -36.79% |
| 2014 Q1 | -1.02 Million SEK | 10.22% |
| 2014 FY | - SEK | -9.29% |
| 2014 Q2 | -1.31 Million SEK | -28.29% |
| 2014 Q3 | -940.23 Thousand SEK | 28.6% |
| 2014 Q4 | -1.58 Million SEK | -68.48% |
| 2013 FY | - SEK | -26.95% |
| 2013 Q3 | -235.39 Thousand SEK | 86.51% |
| 2013 Q1 | -1.74 Million SEK | -68.2% |
| 2013 Q4 | -1.14 Million SEK | -385.76% |
| 2013 Q2 | -1.74 Million SEK | -0.0% |
| 2012 FY | - SEK | -76.57% |
| 2012 Q4 | -1.03 Million SEK | 0.0% |
| 2011 FY | - SEK | 10.28% |
| 2010 FY | - SEK | -52.99% |
| 2009 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | -54.071% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 128.848% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 128.848% |
| Arcoma AB | 6.24 Million SEK | 2001.777% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | -32.052% |
| BICO Group AB (publ) | 322.3 Million SEK | 136.867% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 280.092% |
| CellaVision AB (publ) | 207.24 Million SEK | 157.335% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | -73.703% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -325.234% |
| C-Rad AB (publ) | 48.9 Million SEK | 342.972% |
| Duearity AB (publ) | -24.77 Million SEK | -379.531% |
| Dignitana AB (publ) | -264 Thousand SEK | -44908.712% |
| Episurf Medical AB (publ) | -87.7 Million SEK | -35.488% |
| Getinge AB (publ) | 5.92 Billion SEK | 102.004% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -76.688% |
| Iconovo AB (publ) | -35.33 Million SEK | -236.271% |
| Integrum AB (publ) | 8.76 Million SEK | 1456.19% |
| Luxbright AB (publ) | -23.86 Million SEK | -397.86% |
| Mentice AB (publ) | 28.87 Million SEK | 511.537% |
| OssDsign AB (publ) | -122.02 Million SEK | 2.621% |
| Paxman AB (publ) | 31.22 Million SEK | 480.489% |
| Promimic AB (publ) | -3.68 Million SEK | -3125.381% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 21.05% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -129.26% |
| ScandiDos AB (publ) | -13.35 Million SEK | -789.66% |
| Sectra AB (publ) | 615.06 Million SEK | 119.319% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -129.947% |
| SpectraCure AB (publ) | -20.96 Million SEK | -466.66% |
| Stille AB | 56.04 Million SEK | 312.029% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 96.269% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 193.876% |